These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9031288)
1. Calcitriol may directly suppress bone turnover. Ureña P; Prieur P; Pétrover M Nephron; 1997; 75(1):116-7. PubMed ID: 9031288 [No Abstract] [Full Text] [Related]
2. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Cannella G; Bonucci E; Rolla D; Ballanti P; Moriero E; De Grandi R; Augeri C; Claudiani F; Di Maio G Kidney Int; 1994 Oct; 46(4):1124-32. PubMed ID: 7861707 [TBL] [Abstract][Full Text] [Related]
3. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002 [TBL] [Abstract][Full Text] [Related]
4. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956 [TBL] [Abstract][Full Text] [Related]
5. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. Messa C; Goodman WG; Hoh CK; Choi Y; Nissenson AR; Salusky IB; Phelps ME; Hawkins RA J Clin Endocrinol Metab; 1993 Oct; 77(4):949-55. PubMed ID: 8408470 [TBL] [Abstract][Full Text] [Related]
6. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients. Shiizaki K; Negi S; Mizobuchi M; Hatamura I; Narukawa N; Sakaguchi T; Kitabata Y; Sumikado S; Akizawa T Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii42-6. PubMed ID: 12771299 [TBL] [Abstract][Full Text] [Related]
7. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism. Lu KC; Wu CC; Ma WY; Chen CC; Wu HC; Chu P Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195 [TBL] [Abstract][Full Text] [Related]
9. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3]. Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605 [No Abstract] [Full Text] [Related]
10. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis. Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173 [TBL] [Abstract][Full Text] [Related]
11. [Maxacalcitol, a medicine for secondary hyperparathyroidism (2 degrees HPT)]. Imazeki I Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):65-72. PubMed ID: 12617040 [TBL] [Abstract][Full Text] [Related]
12. Failure to heal D-deficiency rickets and suppress secondary hyperparathyroidism with conventional doses of 1,25-dihydroxy vitamin D3. Cundy T; Kanis JA; Heynen G; Earnshaw M; Clemens TL; O'Riordan JL; Merrett AL; Compston JE Br Med J (Clin Res Ed); 1982 Mar; 284(6319):883-5. PubMed ID: 6279228 [No Abstract] [Full Text] [Related]
13. Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol. Hodson EM; Evans RA; Dunstan CR; Hills E; Wong SY; Rosenberg AR; Roy LP Clin Nephrol; 1985 Oct; 24(4):192-200. PubMed ID: 3877585 [TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Liou HH; Chiang SS; Tsai SC; Chang CC; Wu SC; Shieh SD; Huang TP Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705 [TBL] [Abstract][Full Text] [Related]
15. Renal osteodystrophy in children treated with 1,25-dihydroxy-cholecalciferol [1,25-(OH)2D3]. Histologic bone studies. Robitaille P; Marie PJ; Delvin EE; Lortie L; Glorieux FH Acta Paediatr Scand; 1984 May; 73(3):315-24. PubMed ID: 6547559 [TBL] [Abstract][Full Text] [Related]
16. Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease. Newman CL; Tian N; Hammond MA; Wallace JM; Brown DM; Chen NX; Moe SM; Allen MR Am J Nephrol; 2016; 43(1):20-31. PubMed ID: 26881752 [TBL] [Abstract][Full Text] [Related]
17. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients. Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896 [TBL] [Abstract][Full Text] [Related]